Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the first line of treatment. A fundamental aspect is activation and platelet aggregation, which is why, in addition to creating networks to optimize STEMI treatment, prehospital drug treatments have been implemented. 

Doctor con tabletas de aspirinas

The COMPARECrush looked at whether early and powerful treatment on platelet inhibition through crushed prasugrel in the ambulance might improve epicardial perfusion. Results showed a reduction in early platelet reactivity during primary PCI. However, it remains unclear whether platelet inhibition might benefit a subgroup of high risk patients.  

The aim of this multicenter randomized study was to assess the efficacy of prehospital crushed vs. integral prasugrel loading dose in patients with large myocardial area at risk, reflected by the accumulated ST deviation at ambulance ECG. 

Read also: Biolimus vs Paclitaxel Coated Balloons for the Treatment of In-Stent Restenosis.

Primary end point included flow TIMI 3 in the infarct related artery, high thrombus load and grade 3 blush. The study also looked at clinical outcomes such as all-cause mortality, repeat MI, stent thrombosis, use of IIb/IIIa, stroke and emergency revascularization.

532 patients were included, 62% presenting a large myocardial area at risk. Mean age was 61 in the group of large myocardia area at risk, vs. 63 in the group without large myocardial compromise. Most were men. The most affected artery was the anterior descending, followed by the circumflex and the right coronary artery. 

Read also: Cardioband in Tricuspid Valve Regurgitation.

Crushed prasugrel significantly improved postprocedural TIMI 3 in STEMI patients with large prehospital myocardial area at risk (92 % vs 79 %, OR: 3,00, CI 95%: 1,50-6,00), but not in patients with STEMI without a large prehospital myocardial area at risk (91 % vs 95 %, OR 0,47; CI 95 %: 0,14-1,57; interaction = 0,009). There were no differences in clinical outcomes between the groups. 

Conclusion

This substudy showed a significant effect of prehospital crushed vs integral prasugrel in terms of procedural success in patients with STEMI and a large myocardial area at risk. This finding was reflected by improved final TIMI 3 flow, and represents a fast and cost effective strategy. Even though these data come from a substudy, they should generate hypothesis for future studies. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Prehospital crushed versus integral prasugrel loading dose in STEMI patients with a large myocardial area.

Reference: Jeroen M. Wilschut MD et al EuroIntervention 2024;20:e436-e444.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...